Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Vir Biotechnology stock price, quote, forecast and news

VIR
US92764N1028
A2PS0P

Price

7.83
Today +/-
-0.14
Today %
-1.90 %
P

Vir Biotechnology stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Vir Biotechnology stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Vir Biotechnology stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Vir Biotechnology stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Vir Biotechnology's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Vir Biotechnology Stock Price History

DateVir Biotechnology Price
9/11/20247.83 undefined
9/10/20247.98 undefined
9/9/20247.82 undefined
9/6/20247.76 undefined
9/5/20247.65 undefined
9/4/20247.60 undefined
9/3/20247.78 undefined
8/30/20248.26 undefined
8/29/20248.30 undefined
8/28/20248.27 undefined
8/27/20248.35 undefined
8/26/20248.62 undefined
8/23/20248.77 undefined
8/22/20248.32 undefined
8/21/20248.67 undefined
8/20/20248.81 undefined
8/19/20248.77 undefined
8/16/20248.62 undefined
8/15/20248.66 undefined

Vir Biotechnology Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Vir Biotechnology, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Vir Biotechnology from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Vir Biotechnology’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Vir Biotechnology. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Vir Biotechnology’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Vir Biotechnology’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Vir Biotechnology’s growth potential.

Vir Biotechnology Revenue, EBIT and net profit per share

DateVir Biotechnology RevenueVir Biotechnology EBITVir Biotechnology Net Income
2029e1.53 B undefined0 undefined144.91 M undefined
2028e245.87 M undefined-578.73 M undefined-306.37 M undefined
2027e214.6 M undefined-693.37 M undefined-307.3 M undefined
2026e44.94 M undefined-641.65 M undefined-501.83 M undefined
2025e32.76 M undefined-652.14 M undefined-520.12 M undefined
2024e71.63 M undefined-549.9 M undefined-467.23 M undefined
202386.18 M undefined-684.31 M undefined-615.06 M undefined
20221.62 B undefined833.1 M undefined515.8 M undefined
20211.1 B undefined420.8 M undefined528.6 M undefined
202076.4 M undefined-297 M undefined-298.7 M undefined
20198.1 M undefined-178 M undefined-174.7 M undefined
201810.7 M undefined-118.7 M undefined-115.9 M undefined
20172.7 M undefined-80.8 M undefined-69.9 M undefined

Vir Biotechnology Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20172018201920202021202220232024e2025e2026e2027e2028e2029e
00.010.010.081.11.620.090.070.030.040.210.251.53
-400.00-20.00850.001,340.7947.49-94.67-17.44-54.9337.50386.3614.49523.27
----93.9790.9696.51------
00001.031.470.08000000
-80-118-178-297420833-684-549-652-641-693-5780
-4,000.00-1,180.00-2,225.00-390.7938.3651.58-795.35-773.24-2,037.50-1,456.82-323.83-235.92-
-69-115-174-298528515-615-467-520-501-307-306144
-66.6751.3071.26-277.18-2.46-219.42-24.0711.35-3.65-38.72-0.33-147.06
440.3109.430.3119.2133.4134.8134.13000000
-------------
Details

Keystats

ⓘ

Revenue and Growth

The Vir Biotechnology Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Vir Biotechnology is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (k)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
2017201820192020202120222023
             
0.190.10.380.740.712.41.52
0000773.100
0000000
0000000
4.419.419.635.581.6117.165.82
0.190.120.40.771.562.521.59
5.112.316.379.9130.1188.2167.2
0024.30201.423.9105.28
0000000
35.936.935.733.833.332.822.57
16.916.916.916.916.916.916.94
1.37.715.815.79.821.218.86
59.273.8109146.3391.5283330.83
0.250.190.510.921.952.81.92
             
292.5309.100000.01
0.010.010.791.391.571.711.83
-78-193.8-368.5-667.2-138.6377.2-237.82
0000000
00-0.6-1.3-1.1-9.1-0.82
0.220.130.420.721.432.081.59
4.96.55.95.16.56.46.33
7.514.526.376.7141.5489.1104.22
018.926.817.1193.215.564.85
0000000
00200300000
12.439.959.299.2341.2511175.41
00900700000
3.33.33.33.318.43.30
12.218.424.798.9162.7209.8153.42
15.521.728.9102.9181.1213.1153.42
27.961.688.1202.1522.3724.1328.82
0.250.190.510.921.952.81.92
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Vir Biotechnology provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Vir Biotechnology's financial health and stability.

Assets

Vir Biotechnology's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Vir Biotechnology must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Vir Biotechnology after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Vir Biotechnology's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2017201820192020202120222023
-69-115-174-298528515-615
02455619
-1000015-15-1
412829-628665-304
131241100114592233
0000000
000002522
-0.07-0.09-0.13-0.19-0.051.66-0.78
-2-9-8-6-21-68-21
-30-60-256-9-140-1,193164
-27-50-247-3-119-1,125186
0000000
0040000
27114444534100367
27125449529100347
0100-40-10
0000000
174-12963328-88504-606
-69.1-104-138.5-197.4-69.41,595.3-800.36
0000000

Vir Biotechnology stock margins

The Vir Biotechnology margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Vir Biotechnology. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Vir Biotechnology.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Vir Biotechnology's sales revenue. A higher gross margin percentage indicates that the Vir Biotechnology retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Vir Biotechnology's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Vir Biotechnology's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Vir Biotechnology's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Vir Biotechnology. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Vir Biotechnology's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Vir Biotechnology Margin History

Vir Biotechnology Gross marginVir Biotechnology Profit marginVir Biotechnology EBIT marginVir Biotechnology Profit margin
2029e96.79 %0 %9.49 %
2028e96.79 %-235.38 %-124.61 %
2027e96.79 %-323.1 %-143.2 %
2026e96.79 %-1,427.89 %-1,116.73 %
2025e96.79 %-1,990.49 %-1,587.51 %
2024e96.79 %-767.73 %-652.32 %
202396.79 %-794.04 %-713.69 %
202290.95 %51.56 %31.92 %
202193.99 %38.42 %48.26 %
202096.79 %-388.74 %-390.97 %
201996.79 %-2,197.53 %-2,156.79 %
201896.79 %-1,109.35 %-1,083.18 %
201796.79 %-2,992.59 %-2,588.89 %

Vir Biotechnology Stock Sales Revenue, EBIT, Earnings per Share

The Vir Biotechnology earnings per share therefore indicates how much revenue Vir Biotechnology has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Vir Biotechnology earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Vir Biotechnology's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Vir Biotechnology’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Vir Biotechnology's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Vir Biotechnology Revenue, EBIT and net profit per share

DateVir Biotechnology Sales per ShareVir Biotechnology EBIT per shareVir Biotechnology Earnings per Share
2029e11.18 undefined0 undefined1.06 undefined
2028e1.8 undefined0 undefined-2.24 undefined
2027e1.57 undefined0 undefined-2.25 undefined
2026e0.33 undefined0 undefined-3.67 undefined
2025e0.24 undefined0 undefined-3.81 undefined
2024e0.52 undefined0 undefined-3.42 undefined
20230.64 undefined-5.1 undefined-4.59 undefined
202211.99 undefined6.18 undefined3.83 undefined
20218.21 undefined3.15 undefined3.96 undefined
20200.64 undefined-2.49 undefined-2.51 undefined
20190.27 undefined-5.87 undefined-5.77 undefined
20180.1 undefined-1.09 undefined-1.06 undefined
20170.01 undefined-0.18 undefined-0.16 undefined

Vir Biotechnology business model

Vir Biotechnology Inc. is a biopharmaceutical company focused on the development of therapeutics to combat infectious diseases. The company was founded in 2016 by George Scangos, former CEO of Biogen, and Bob Nelsen, co-founder of Arch Venture Partners. History: Vir Biotechnology originated from a collaboration between Arch Venture Partners and the biotechnology incubator, The Infectious Disease Research Institute (IDRI), to develop therapeutics against Ebola viruses. In 2016, they founded Vir Biotechnology with an initial capital of $150 million from various investors, including SoftBank and the Bill & Melinda Gates Foundation. The company received an additional capital injection of $250 million in 2018 and went public in the same year. Business model: Vir Biotechnology builds on its proprietary technology platform, which focuses on antibody identification. The company collaborates with various partners, including Biogen and Alnylam Pharmaceuticals, to utilize its technology for the development of therapeutics against infectious diseases such as COVID-19, influenza, rabbit fever, and the Zika virus. Vir Biotechnology also has several pipeline programs in clinical development, including VIR-7831, VIR-2703, and VIR-2482. VIR-7831 is a monoclonal antibody developed for the treatment of COVID-19 and is currently in phase 3 clinical trials. VIR-2703 is an inactive RNA vaccine developed for the prevention of COVID-19 and is currently in phase 2 clinical trials. VIR-2482 is a universal influenza vaccine recently investigated in a phase 1/2a clinical trial. Divisions: Vir Biotechnology has focused on three main divisions: infectious diseases, immuno-oncology therapy, and neurodegenerative diseases. In the field of infectious diseases, the company works on the development of therapeutics against viruses such as COVID-19, respiratory syncytial virus (RSV), West Nile virus, and influenza virus. In the field of immuno-oncology therapy, the company works on the development of therapeutics against cancer. And in the field of neurodegenerative diseases, the company works on the development of therapeutics against diseases such as Alzheimer's and Parkinson's. Products: VIR-7831 is a monoclonal antibody developed for the treatment of COVID-19. The antibody binds to the spike protein of the virus and blocks its interaction with ACE2 receptors in human cells. It is currently being tested in phase 3 clinical trials. VIR-2703 is a well-tolerated RNA vaccine developed for the prevention of COVID-19. It contains an inactivated form of the virus that stimulates the immune system to produce antibodies against the virus. It is currently being tested in phase 2 clinical trials. VIR-2482 is a universal influenza vaccine developed to cover a broader spectrum of influenza viruses than conventional flu vaccines. The vaccine contains a combination of antibodies against various strains of the influenza virus and was recently investigated in a phase 1/2a clinical trial. Summary: Vir Biotechnology is a biopharmaceutical company focused on the development of therapeutics to combat infectious diseases. The company has a proprietary technology platform for antibody identification and collaborates with various partners to utilize this technology for the development of therapeutics against a variety of diseases. The company has several pipeline programs in clinical development, including VIR-7831, VIR-2703, and VIR-2482, as well as research programs in the fields of immuno-oncology and neurodegeneration. The translation is: Vir Biotechnology Inc. is a biopharmaceutical company that focuses on the development of therapeutics to combat infectious diseases. The company was founded in 2016 by George Scangos, former CEO of Biogen, and Bob Nelsen, co-founder of Arch Venture Partners. History: Vir Biotechnology originated from a collaboration between Arch Venture Partners and the biotechnology incubator, The Infectious Disease Research Institute (IDRI), to develop therapeutics against Ebola viruses. In 2016, they founded Vir Biotechnology with an initial capital of $150 million from various investors, including SoftBank and the Bill & Melinda Gates Foundation. The company received an additional capital injection of $250 million in 2018 and went public in the same year. Business model: Vir Biotechnology builds on its proprietary technology platform, which focuses on antibody identification. The company collaborates with various partners, including Biogen and Alnylam Pharmaceuticals, to utilize its technology for the development of therapeutics against infectious diseases such as COVID-19, influenza, rabbit fever, and the Zika virus. Vir Biotechnology also has several pipeline programs in clinical development, including VIR-7831, VIR-2703, and VIR-2482. VIR-7831 is a monoclonal antibody developed for the treatment of COVID-19 and is currently in phase 3 clinical trials. VIR-2703 is an inactive RNA vaccine developed for the prevention of COVID-19 and is currently in phase 2 clinical trials. VIR-2482 is a universal influenza vaccine recently investigated in a phase 1/2a clinical trial. Divisions: Vir Biotechnology has focused on three main divisions: infectious diseases, immuno-oncology therapy, and neurodegenerative diseases. In the field of infectious diseases, the company works on the development of therapeutics against viruses such as COVID-19, respiratory syncytial virus (RSV), West Nile virus, and influenza virus. In the field of immuno-oncology therapy, the company works on the development of therapeutics against cancer. And in the field of neurodegenerative diseases, the company works on the development of therapeutics against diseases such as Alzheimer's and Parkinson's. Products: VIR-7831 is a monoclonal antibody developed for the treatment of COVID-19. The antibody binds to the spike protein of the virus and blocks its interaction with ACE2 receptors in human cells. It is currently being tested in phase 3 clinical trials. VIR-2703 is a well-tolerated RNA vaccine developed for the prevention of COVID-19. It contains an inactivated form of the virus that stimulates the immune system to produce antibodies against the virus. It is currently being tested in phase 2 clinical trials. VIR-2482 is a universal influenza vaccine developed to cover a broader spectrum of influenza viruses than conventional flu vaccines. The vaccine contains a combination of antibodies against various strains of the influenza virus and was recently investigated in a phase 1/2a clinical trial. Summary: Vir Biotechnology is a biopharmaceutical company focused on the development of therapeutics to combat infectious diseases. The company has a proprietary technology platform for antibody identification and collaborates with various partners to utilize this technology for the development of therapeutics against a variety of diseases. The company has several pipeline programs in clinical development, including VIR-7831, VIR-2703, and VIR-2482, as well as research programs in the fields of immuno-oncology and neurodegeneration. Vir Biotechnology is one of the most popular companies on Eulerpool.com.

Vir Biotechnology SWOT Analysis

Strengths

Vir Biotechnology Inc has several strengths that provide it with a competitive advantage:

  • Strong scientific expertise and research capabilities
  • Partnerships with leading pharmaceutical companies
  • Advanced technology platforms
  • Robust pipeline of innovative drug candidates
  • Experienced management team

Weaknesses

While Vir Biotechnology Inc enjoys various strengths, it also faces certain weaknesses:

  • Limited financial resources
  • Dependence on external partnerships for funding and development
  • Relatively small market presence compared to larger competitors
  • Potential difficulties in obtaining regulatory approvals
  • Inherent risks associated with drug development

Opportunities

Vir Biotechnology Inc can capitalize on the following opportunities:

  • Growing demand for effective treatments for infectious diseases
  • Increasing focus on personalized medicine and precision therapies
  • Expanding global biopharmaceutical market
  • Potential partnerships and collaborations with academic institutions
  • Advancements in technology and data analytics in the healthcare industry

Threats

There are several potential threats that Vir Biotechnology Inc should consider:

  • Rapidly evolving competitive landscape
  • Stringent regulatory requirements and potential delays
  • Possible negative impact of healthcare reforms and policy changes
  • Intellectual property infringement by competitors
  • Adverse events or unexpected side effects during clinical trials

Vir Biotechnology Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Vir Biotechnology historical P/E ratio, EBIT, and P/S ratio.

Vir Biotechnology shares outstanding

The number of shares was Vir Biotechnology in 2023 — This indicates how many shares 134.131 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Vir Biotechnology earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Vir Biotechnology's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Vir Biotechnology’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Vir Biotechnology's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Vir Biotechnology.

Vir Biotechnology latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.9 -1.02  (-12.81 %)2024 Q2
3/31/2024-1.06 -0.48  (54.8 %)2024 Q1
12/31/2023-1.02 -0.86  (15.51 %)2023 Q4
9/30/2023-1.22 -1.22  (-0.2 %)2023 Q3
6/30/2023-1.22 -1.45  (-19.3 %)2023 Q2
3/31/2023-0.88 -1.06  (-20.02 %)2023 Q1
12/31/2022-0.4 -0.76  (-90.48 %)2022 Q4
9/30/2022-0.22 1.3  (704.37 %)2022 Q3
6/30/20220.11 -0.58  (-648.2 %)2022 Q2
3/31/20223.82 3.85  (0.84 %)2022 Q1
1
2

Eulerpool ESG Scorecard© for the Vir Biotechnology stock

Eulerpool World ESG Rating (EESG©)

54/ 100

🌱 Environment

36

👫 Social

66

🏛️ Governance

60

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Vir Biotechnology list of shareholders

%
Name
Stocks
Change
Date
9.45306 % ARCH Venture Partners12,916,6633,377,4799/9/2022
8.98847 % The Vanguard Group, Inc.12,281,8431,096,47312/31/2023
6.25802 % GSK plc8,550,95404/3/2023
5.05861 % State Street Global Advisors (US)6,912,082-261,34612/31/2023
4.17457 % Scangos (George A)5,704,138-55,5002/26/2024
2.90219 % Baillie Gifford & Co.3,965,549-6,02212/31/2023
2.22332 % Citadel Advisors LLC3,037,9482,954,40912/31/2023
2.03531 % AllianceBernstein L.P.2,781,049-116,68512/31/2023
12.21022 % SB Investment Advisers (UK) Limited16,684,041012/31/2023
10.59104 % BlackRock Institutional Trust Company, N.A.14,471,596865,18412/31/2023
1
2
3
4
5
...
10

Vir Biotechnology Executives and Management Board

Dr. Phil Pang48
Vir Biotechnology Executive Vice President, Chief Medical Officer, Interim Head of Research
Compensation 4.39 M
Dr. Ann Hanly53
Vir Biotechnology Executive Vice President, Chief Technology Officer
Compensation 3.58 M
Mr. Steven Rice63
Vir Biotechnology Executive Vice President, Chief Administrative Officer
Compensation 2.17 M
Dr. Vicki Sato74
Vir Biotechnology Independent Chairman of the Board
Compensation 488,214
Mr. Robert More55
Vir Biotechnology Independent Director
Compensation 464,940
1
2
3
4

Most common questions regarding Vir Biotechnology

What values and corporate philosophy does Vir Biotechnology represent?

Vir Biotechnology Inc is a leading biotechnology company with a strong focus on innovation and scientific excellence. The company's core values revolve around integrity, collaboration, and a commitment to improving patient health. Vir Biotechnology Inc believes in leveraging cutting-edge technologies to develop novel therapeutic solutions for the most challenging infectious diseases. With a mission to address global health concerns, the company combines its extensive expertise in immunology and infectious diseases to create transformative treatments and preventive measures. Vir Biotechnology Inc's corporate philosophy centers around the belief that every patient deserves access to safe and effective therapies.

In which countries and regions is Vir Biotechnology primarily present?

Vir Biotechnology Inc is primarily present in the United States.

What significant milestones has the company Vir Biotechnology achieved?

Vir Biotechnology Inc has achieved several significant milestones in its journey. The company successfully completed its initial public offering (IPO) in October 2019, raising substantial capital to support its research and development efforts. Vir Biotechnology has also formed multiple strategic collaborations with renowned pharmaceutical companies, including Gilead Sciences and GlaxoSmithKline, to advance its pipeline of innovative therapies. Furthermore, Vir Biotechnology received fast-track designation from the U.S. Food and Drug Administration (FDA) for its potential therapy for hepatitis B virus infection. These accomplishments demonstrate Vir Biotechnology's commitment to progress and innovation in the field of biotechnology.

What is the history and background of the company Vir Biotechnology?

Vir Biotechnology Inc. is a renowned company with an impressive history and background. Founded in 2016, Vir Biotechnology is a clinical-stage immunology company focused on developing therapeutic solutions for severe infectious diseases. The company is committed to utilizing cutting-edge technologies to address global health challenges. Vir Biotechnology has established strategic partnerships with world-leading institutions and has a diverse portfolio of innovative treatments. With its relentless dedication to scientific excellence and unwavering commitment to public health, Vir Biotechnology Inc. has gained significant recognition and continues to be at the forefront of advancing breakthrough treatments for infectious diseases worldwide.

Who are the main competitors of Vir Biotechnology in the market?

Vir Biotechnology Inc has several main competitors in the market. Some of the notable competitors of Vir Biotechnology Inc include Gilead Sciences Inc, Moderna Inc, and Regeneron Pharmaceuticals Inc. These companies operate in the field of biotechnology and pharmaceuticals, specializing in developing innovative therapies, treatments, and vaccines. With their focus on advancing biomedical research and developing breakthrough solutions, the competitive landscape for Vir Biotechnology Inc remains intense. However, Vir Biotechnology Inc strives to stay at the forefront of the industry by leveraging its expertise and partnerships to address global health challenges and deliver value to its stakeholders.

In which industries is Vir Biotechnology primarily active?

Vir Biotechnology Inc is primarily active in the biotechnology industry.

What is the business model of Vir Biotechnology?

Vir Biotechnology Inc's business model is focused on developing novel therapies to combat serious infectious diseases. The company utilizes cutting-edge technologies and a deep understanding of the immune system to develop treatments for viral infections. Vir Biotechnology aims to address unmet medical needs by harnessing the power of antiviral antibodies and other approaches to provide innovative solutions. With a strong pipeline and strategic partnerships, Vir Biotechnology is dedicated to advancing breakthrough therapies to improve global public health.

What is the P/E ratio of Vir Biotechnology 2024?

The Vir Biotechnology P/E ratio is -2.25.

What is the P/S ratio of Vir Biotechnology 2024?

The Vir Biotechnology P/S ratio is 14.66.

What is the AlleAktien quality score of Vir Biotechnology?

The AlleAktien quality score for Vir Biotechnology is 2/10.

What is the revenue of Vir Biotechnology 2024?

The expected Vir Biotechnology revenue is 71.63 M USD.

How high is the profit of Vir Biotechnology 2024?

The expected Vir Biotechnology profit is -467.23 M USD.

What is the business model of Vir Biotechnology

Vir Biotechnology Inc. is a young biopharmaceutical company that focuses on combating infectious diseases. The company relies on a combination of scientific expertise, innovative technologies, and extensive partnerships to develop advanced therapies and vaccines against some of the world's most dangerous viruses. The company specializes in three main areas: infectious diseases, immunology, and oncology. In the field of infectious diseases, Vir Biotechnology focuses on developing drugs for serious viral infections such as HIV, hepatitis B, cytomegalovirus, and influenza. In the field of immunology, the company explores the mechanisms underlying the immune system to find new ways to treat autoimmune and inflammatory diseases. Additionally, Vir is working on developing cancer immunotherapies and personalized therapy approaches for the fight against cancer. The company works closely with a range of partners, including universities, research institutions, and biopharmaceutical companies. In 2020, Vir entered into a collaboration agreement with biotechnology company GSK to jointly develop antibodies against COVID-19. A key part of Vir Biotechnology's business model is research and development of new therapies and vaccines. The company heavily invests in its research facilities in San Francisco, California and Cambridge, United Kingdom to develop new technologies and solutions. Vir has already brought several products to market, including a new antibody preparation for the treatment of influenza and a personalized immunotherapy for cancer. Additionally, the company aims to develop a variety of products and technologies to combat infectious diseases, including viral vectors, RNA- and DNA-based therapies, and new immunotherapies. Vir Biotechnology's business model also includes a strong capital raising strategy. The company has already completed several funding rounds and successfully gone public to support its growth and advancement. In summary, Vir Biotechnology is an innovative biopharmaceutical company that is developing a wide range of products and technologies to combat infectious diseases, autoimmune diseases, and cancer. The company relies on scientific expertise, partnerships, and a strong capital raising strategy to promote the growth and development of its business. With a dedicated focus on research and development and a strong pipeline of products and therapies, Vir Biotechnology remains a key player in the fight against infectious diseases and other serious conditions. Vir Biotechnology Inc. is a young biopharmaceutical company that focuses on combating infectious diseases. The company relies on a combination of scientific expertise, innovative technologies, and extensive partnerships to develop advanced therapies and vaccines against some of the world's most dangerous viruses. The company specializes in three main areas: infectious diseases, immunology, and oncology. In the field of infectious diseases, Vir Biotechnology focuses on developing drugs for serious viral infections such as HIV, hepatitis B, cytomegalovirus, and influenza. In the field of immunology, the company explores the mechanisms underlying the immune system to find new ways to treat autoimmune and inflammatory diseases. Additionally, Vir is working on developing cancer immunotherapies and personalized therapy approaches for the fight against cancer. The company works closely with a range of partners, including universities, research institutions, and biopharmaceutical companies. In 2020, Vir entered into a collaboration agreement with biotechnology company GSK to jointly develop antibodies against COVID-19. A key part of Vir Biotechnology's business model is research and development of new therapies and vaccines. The company heavily invests in its research facilities in San Francisco, California and Cambridge, United Kingdom to develop new technologies and solutions. Vir has already brought several products to market, including a new antibody preparation for the treatment of influenza and a personalized immunotherapy for cancer. Additionally, the company aims to develop a variety of products and technologies to combat infectious diseases, including viral vectors, RNA- and DNA-based therapies, and new immunotherapies. Vir Biotechnology's business model also includes a strong capital raising strategy. The company has already completed several funding rounds and successfully gone public to support its growth and advancement. In summary, Vir Biotechnology is an innovative biopharmaceutical company that is developing a wide range of products and technologies to combat infectious diseases, autoimmune diseases, and cancer. The company relies on scientific expertise, partnerships, and a strong capital raising strategy to promote the growth and development of its business. With a dedicated focus on research and development and a strong pipeline of products and therapies, Vir Biotechnology remains a key player in the fight against infectious diseases and other serious conditions.

What is the Vir Biotechnology dividend?

Vir Biotechnology pays a dividend of 0 USD distributed over payouts per year.

How often does Vir Biotechnology pay dividends?

The dividend cannot currently be calculated for Vir Biotechnology or the company does not pay out a dividend.

What is the Vir Biotechnology ISIN?

The ISIN of Vir Biotechnology is US92764N1028.

What is the Vir Biotechnology WKN?

The WKN of Vir Biotechnology is A2PS0P.

What is the Vir Biotechnology ticker?

The ticker of Vir Biotechnology is VIR.

How much dividend does Vir Biotechnology pay?

Over the past 12 months, Vir Biotechnology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Vir Biotechnology is expected to pay a dividend of 0 USD.

What is the dividend yield of Vir Biotechnology?

The current dividend yield of Vir Biotechnology is .

When does Vir Biotechnology pay dividends?

Vir Biotechnology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Vir Biotechnology?

Vir Biotechnology paid dividends every year for the past 0 years.

What is the dividend of Vir Biotechnology?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Vir Biotechnology located?

Vir Biotechnology is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vir Biotechnology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vir Biotechnology from 9/14/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/14/2024.

When did Vir Biotechnology pay the last dividend?

The last dividend was paid out on 9/14/2024.

What was the dividend of Vir Biotechnology in the year 2023?

In the year 2023, Vir Biotechnology distributed 0 USD as dividends.

In which currency does Vir Biotechnology pay out the dividend?

The dividends of Vir Biotechnology are distributed in USD.

All fundamentals about Vir Biotechnology

Our stock analysis for Vir Biotechnology Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vir Biotechnology Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.